Skip to navigation Skip to content



About this Medication
  • Brand Name: Plegridy® (PLEGG-rih-dee)
  • Chemical Name: peginterferon beta-1a (peg-inter-FEER-on BAY-ta-wun-ay)
  • Usage in MS: Disease-Modifying Agent
  • Generic Available: No

This is an injectable medication.



Pegylated interferon beta-1a is a “pegylated" form of interferon, meaning that polyethylene glycol is attached to the interferon molecules to allow them to maintain their biologic effects in the body for longer periods of time. Because the biologic effects in the body last longer, dosing can occur at less frequent intervals.

This medication is manufactured by a biotechnological process from one of the naturally-occurring interferons (a type of protein). It is made up of exactly the same amino acids (major components of proteins) as the interferon beta found in the human body.

Plegridy is approved by the FDA for the treatment of relapsing forms of multiple sclerosis, which include clinically isolated syndrome, relapsing-remitting disease (RRMS) and active secondary progressive disease (SPMS with relapses).

Click here to read the Plegridy prescribing information for healthcare providers.

Click here to read the Plegridy Medication Guide for patients.


Plegridy support services:
Biogen Options 

Financial Assistance Program

Biogen Options


© 2024 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.